Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P9YP
|
|||
| Former ID |
DIB004960
|
|||
| Drug Name |
AVP-13358
|
|||
| Synonyms |
IgE inhibitors, AVANIR; Allergy/asthma therapeutic, AVANIR
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Rhinitis [ICD-11: FA20; ICD-10: J31.0] | Phase 1 | [1] | |
| Company |
AVANIR Pharmaceuticals Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C30H29N5O2
|
|||
| Canonical SMILES |
C1C2CC3CC1CC(C2)(C3)C(=O)NC4=CC=C(C=C4)C5=NC6=C(N5)C=C(C=C6)C(=O)NC7=CC=CC=N7
|
|||
| InChI |
1S/C30H29N5O2/c36-28(35-26-3-1-2-10-31-26)22-6-9-24-25(14-22)34-27(33-24)21-4-7-23(8-5-21)32-29(37)30-15-18-11-19(16-30)13-20(12-18)17-30/h1-10,14,18-20H,11-13,15-17H2,(H,32,37)(H,33,34)(H,31,35,36)
|
|||
| InChIKey |
LUPHOOKVGNVAFT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 459805-03-9
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Immunoglobulin E (IgE) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | AVANIR Reports Positive Interim Phase I Safety Data on Asthma/Allergy Drug Candidate; Potential Asthma/Allergy Product Modulates IgE and Th2 Cytokines Orally | |||
| REF 2 | Novel 2-(substituted phenyl)benzimidazole derivatives with potent activity against IgE, cytokines, and CD23 for the treatment of allergy and asthma. J Med Chem. 2004 Dec 16;47(26):6451-4. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.